Budget Amount *help |
¥103,740,000 (Direct Cost: ¥79,800,000、Indirect Cost: ¥23,940,000)
Fiscal Year 2014: ¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2013: ¥20,280,000 (Direct Cost: ¥15,600,000、Indirect Cost: ¥4,680,000)
Fiscal Year 2012: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2011: ¥21,060,000 (Direct Cost: ¥16,200,000、Indirect Cost: ¥4,860,000)
Fiscal Year 2010: ¥21,710,000 (Direct Cost: ¥16,700,000、Indirect Cost: ¥5,010,000)
|
Outline of Final Research Achievements |
We tried to identify the therapeutic targets and biomarkers of uncharacterized chemical compound by genomics analysis of the resistant sub-clone cells and functional genomics screening. We also established the antigen receptor repertoire analysis technology of tumor infiltrating lymphocytes for biomarker discovery of the cancer immunotherapy. For diffuse-type gastric cancer, where the valid molecular target is absent, we performed the whole exome sequencing and have identified RHOA driver gene mutations as potential therapeutic targets.
|